Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion's Brazilian subsidiary will supply 660,000 vials of Herzuma to the Brazilian federal government by 2025

Celltrion's Herzuma
Celltrion's Herzuma
Dae-Kyu Ahn 1
2024-09-13 15:01:00 powerzanic@hankyung.com
Bio & Pharma

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ingredient: trastuzumab) won a bid from the Brazilian federal government, marking the fifth consecutive year of supply.

As a result, Celltrion's Brazilian subsidiary will exclusively supply 660,000 vials of Herzuma to the federal government until next year.

Celltrion explained that its local network and stable supply chain, established through its Brazilian subsidiary, contributed to securing this contract.

In addition, Celltrion stated that it has agreed to supply an extra 90,000 vials of the autoimmune disease treatment "Remsima" (active ingredient: infliximab) this year, at the request of the Brazilian federal government. 

Celltrion's headquarters in Incheon, Korea
Celltrion's headquarters in Incheon, Korea

"We will focus on solidifying the market dominance of existing products like Herzuma, while continuing to achieve results with follow-up products such as Vegzelma, which is scheduled for launch in the second half of this year," said Kang Kyung-Doo, head of Celltrion’s Latin America division.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
#Celltrion #Herzuma #trastuzumab #Remsima #infliximab

Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion founder and Chairman Seo Jung-jin speaks at Korea Investment Week on Sept. 11 Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract development and manufacturing organization (CDMO) market, led by Swis

Celltrion chairman announces venture into CDMO market

Celltrion chairman announces venture into CDMO market

Seo Jung-jin (center) speaks at Morgan Stanley 22nd Annual Global Healthcre Conference (Courtesy of Celltrion) South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the company said on Monday, citing its foun

Celltrion scraps merger with Celltrion Pharm

Celltrion scraps merger with Celltrion Pharm

Celltrion founder and Chairman Seo Jung-jin South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&D and local distribution affiliate, in the face of opposition from minority shareholders.They argued th

Costco sells Celltrion's Yuflyma Low WAC in US

Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now available for purchase at Costco in the US.According to Celltrion, Yuflyma was registered earlier this month under the Costco Membership Prescription P

Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion booth at the BIO International Convention 2024 in San Diego, June 2024 (Courtesy of Yonhap) Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, a treatment for non-small cell lung cancer, a
(* comment hide *}